266 related articles for article (PubMed ID: 30559168)
1. Dopamine Receptor D5 is a Modulator of Tumor Response to Dopamine Receptor D2 Antagonism.
Prabhu VV; Madhukar NS; Gilvary C; Kline CLB; Oster S; El-Deiry WS; Elemento O; Doherty F; VanEngelenburg A; Durrant J; Tarapore RS; Deacon S; Charter N; Jung J; Park DM; Gilbert MR; Rusert J; Wechsler-Reya R; Arrillaga-Romany I; Batchelor TT; Wen PY; Oster W; Allen JE
Clin Cancer Res; 2019 Apr; 25(7):2305-2313. PubMed ID: 30559168
[TBL] [Abstract][Full Text] [Related]
2. Role of Dopamine Receptors in the Anticancer Activity of ONC201.
Kline CLB; Ralff MD; Lulla AR; Wagner JM; Abbosh PH; Dicker DT; Allen JE; El-Deiry WS
Neoplasia; 2018 Jan; 20(1):80-91. PubMed ID: 29216597
[TBL] [Abstract][Full Text] [Related]
3. Biological activity of weekly ONC201 in adult recurrent glioblastoma patients.
Arrillaga-Romany I; Odia Y; Prabhu VV; Tarapore RS; Merdinger K; Stogniew M; Oster W; Allen JE; Mehta M; Batchelor TT; Wen PY
Neuro Oncol; 2020 Jan; 22(1):94-102. PubMed ID: 31702782
[TBL] [Abstract][Full Text] [Related]
4. Pharmacological Characterization of the Imipridone Anticancer Drug ONC201 Reveals a Negative Allosteric Mechanism of Action at the D
Free RB; Cuoco CA; Xie B; Namkung Y; Prabhu VV; Willette BKA; Day MM; Sanchez-Soto M; Lane JR; Laporte SA; Shi L; Allen JE; Sibley DR
Mol Pharmacol; 2021 Oct; 100(4):372-387. PubMed ID: 34353882
[TBL] [Abstract][Full Text] [Related]
5. Metabolic and inflammatory reprogramming of macrophages by ONC201 translates in a pro-inflammatory environment even in presence of glioblastoma cells.
Geiß C; Witzler C; Poschet G; Ruf W; Régnier-Vigouroux A
Eur J Immunol; 2021 May; 51(5):1246-1261. PubMed ID: 33442873
[TBL] [Abstract][Full Text] [Related]
6. ONC201 induces the unfolded protein response (UPR) in high- and low-grade ovarian carcinoma cell lines and leads to cell death regardless of platinum sensitivity.
Rumman M; Buck S; Polin L; Dzinic S; Boerner J; Winer IS
Cancer Med; 2021 May; 10(10):3373-3387. PubMed ID: 33932119
[TBL] [Abstract][Full Text] [Related]
7. ONC201 and imipridones: Anti-cancer compounds with clinical efficacy.
Prabhu VV; Morrow S; Rahman Kawakibi A; Zhou L; Ralff M; Ray J; Jhaveri A; Ferrarini I; Lee Y; Parker C; Zhang Y; Borsuk R; Chang WI; Honeyman JN; Tavora F; Carneiro B; Raufi A; Huntington K; Carlsen L; Louie A; Safran H; Seyhan AA; Tarapore RS; Schalop L; Stogniew M; Allen JE; Oster W; El-Deiry WS
Neoplasia; 2020 Dec; 22(12):725-744. PubMed ID: 33142238
[TBL] [Abstract][Full Text] [Related]
8. Selective DRD2 antagonist and ClpP agonist ONC201 in a recurrent non-midline H3 K27M-mutant glioma cohort.
Odia Y; Hall MD; Cloughesy TF; Wen PY; Arrillaga-Romany I; Daghistani D; Mehta MP; Tarapore RS; Ramage SC; Allen JE
Neuro Oncol; 2024 May; 26(Supplement_2):S165-S172. PubMed ID: 38386699
[TBL] [Abstract][Full Text] [Related]
9. Epidermal growth factor receptor as a molecular determinant of glioblastoma response to dopamine receptor D2 inhibitors.
He Y; Li J; Koga T; Ma J; Dhawan S; Suzuki Y; Furnari F; Prabhu VV; Allen JE; Chen CC
Neuro Oncol; 2021 Mar; 23(3):400-411. PubMed ID: 32830856
[TBL] [Abstract][Full Text] [Related]
10. EZH2i EPZ-6438 and HDACi vorinostat synergize with ONC201/TIC10 to activate integrated stress response, DR5, reduce H3K27 methylation, ClpX and promote apoptosis of multiple tumor types including DIPG.
Zhang Y; Zhou L; Safran H; Borsuk R; Lulla R; Tapinos N; Seyhan AA; El-Deiry WS
Neoplasia; 2021 Aug; 23(8):792-810. PubMed ID: 34246076
[TBL] [Abstract][Full Text] [Related]
11. [Role of dopamine receptor subtypes DRD2 and DRD5 in drug therapy of pituitary tumors].
Liu YT; Zhang Y; Wang Y; Wu ZB
Zhonghua Yi Xue Za Zhi; 2019 Jun; 99(22):1703-1706. PubMed ID: 31216815
[No Abstract] [Full Text] [Related]
12. Pediatric and adult H3 K27M-mutant diffuse midline glioma treated with the selective DRD2 antagonist ONC201.
Chi AS; Tarapore RS; Hall MD; Shonka N; Gardner S; Umemura Y; Sumrall A; Khatib Z; Mueller S; Kline C; Zaky W; Khatua S; Weathers SP; Odia Y; Niazi TN; Daghistani D; Cherrick I; Korones D; Karajannis MA; Kong XT; Minturn J; Waanders A; Arillaga-Romany I; Batchelor T; Wen PY; Merdinger K; Schalop L; Stogniew M; Allen JE; Oster W; Mehta MP
J Neurooncol; 2019 Oct; 145(1):97-105. PubMed ID: 31456142
[TBL] [Abstract][Full Text] [Related]
13. Targeting dopamine receptor D2 as a novel therapeutic strategy in endometrial cancer.
Pierce SR; Fang Z; Yin Y; West L; Asher M; Hao T; Zhang X; Tucker K; Staley A; Fan Y; Sun W; Moore DT; Xu C; Tsai YH; Parker J; Prabhu VV; Allen JE; Lee D; Zhou C; Bae-Jump V
J Exp Clin Cancer Res; 2021 Feb; 40(1):61. PubMed ID: 33557912
[TBL] [Abstract][Full Text] [Related]
14. Effects of the DRD2/3 antagonist ONC201 and radiation in glioblastoma.
He L; Bhat K; Ioannidis A; Zhang L; Nguyen NT; Allen JE; Nghiemphu PL; Cloughesy TF; Liau LM; Kornblum HI; Pajonk F
Radiother Oncol; 2021 Aug; 161():140-147. PubMed ID: 34097975
[TBL] [Abstract][Full Text] [Related]
15. Dopamine receptor D2 regulates glioblastoma survival and death through MET and death receptor 4/5.
Jeon HM; Oh YT; Shin YJ; Chang N; Kim D; Woo D; Yeup Y; Joo KM; Jo H; Yang H; Lee JK; Kang W; Sa J; Lee WJ; Hale J; Lathia JD; Purow B; Park MJ; Park JB; Nam DH; Lee J
Neoplasia; 2023 May; 39():100894. PubMed ID: 36972629
[TBL] [Abstract][Full Text] [Related]
16. Cancer stem cell-related gene expression as a potential biomarker of response for first-in-class imipridone ONC201 in solid tumors.
Prabhu VV; Lulla AR; Madhukar NS; Ralff MD; Zhao D; Kline CLB; Van den Heuvel APJ; Lev A; Garnett MJ; McDermott U; Benes CH; Batchelor TT; Chi AS; Elemento O; Allen JE; El-Deiry WS
PLoS One; 2017; 12(8):e0180541. PubMed ID: 28767654
[TBL] [Abstract][Full Text] [Related]
17. Safety and enhanced immunostimulatory activity of the DRD2 antagonist ONC201 in advanced solid tumor patients with weekly oral administration.
Stein MN; Malhotra J; Tarapore RS; Malhotra U; Silk AW; Chan N; Rodriguez L; Aisner J; Aiken RD; Mayer T; Haffty BG; Newman JH; Aspromonte SM; Bommareddy PK; Estupinian R; Chesson CB; Sadimin ET; Li S; Medina DJ; Saunders T; Frankel M; Kareddula A; Damare S; Wesolowsky E; Gabel C; El-Deiry WS; Prabhu VV; Allen JE; Stogniew M; Oster W; Bertino JR; Libutti SK; Mehnert JM; Zloza A
J Immunother Cancer; 2019 May; 7(1):136. PubMed ID: 31118108
[TBL] [Abstract][Full Text] [Related]
18. Activation of DRD5 (dopamine receptor D5) inhibits tumor growth by autophagic cell death.
Leng ZG; Lin SJ; Wu ZR; Guo YH; Cai L; Shang HB; Tang H; Xue YJ; Lou MQ; Zhao W; Le WD; Zhao WG; Zhang X; Wu ZB
Autophagy; 2017 Aug; 13(8):1404-1419. PubMed ID: 28613975
[TBL] [Abstract][Full Text] [Related]
19. First clinical experience with DRD2/3 antagonist ONC201 in H3 K27M-mutant pediatric diffuse intrinsic pontine glioma: a case report.
Hall MD; Odia Y; Allen JE; Tarapore R; Khatib Z; Niazi TN; Daghistani D; Schalop L; Chi AS; Oster W; Mehta MP
J Neurosurg Pediatr; 2019 Apr; 23(6):719-725. PubMed ID: 30952114
[TBL] [Abstract][Full Text] [Related]
20. ONC201 Shows Potent Anticancer Activity Against Medullary Thyroid Cancer via Transcriptional Inhibition of
Bagheri-Yarmand R; Dadu R; Ye L; Shiny Jebaraj Y; Martinez JA; Ma J; Tarapore RS; Allen JE; Sherman SI; Williams MD; Gagel RF
Mol Cancer Ther; 2021 Apr; 20(4):665-675. PubMed ID: 33536187
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]